Author: CAPAHC
-
Health Canada approves DAKLINZA
This all-oral therapy without interferon and ribavirin was approved today by Health Canada.
-
At last, two new meds in Quebec
The CAPAHC is pleased with the Québec Ministry of Health and Social Services’ decision to add Harvoni and Holkira Pak to the list of medications that are covered by the RAMQ.
-
World Hepatitis Day 2015 : July 28th
This year, focus on prevention. To read more
-
The Canadian Drug Expert Committee (CDEC) recommends Holkira Pak
Clinical criterion: Liver fibrosis stage of ≥ 2.
-
Treatment with Ledipasvir and Sofosbuvir Improves Patient-Reported Outcomes
Treatment with interferon (IFN) and ribavirin (RBV) significantly impairs quality of life and other patient-reported outcomes (PROs). Patient experience with IFN- and RBV-free anti-HCV (hepatitis C virus) regimens has not been reported. We assessed PROs in patients treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV.
-
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C
— Harvoni Provides High Cure Rates (SVR12), Shortens Treatment Duration and Eliminates Need for Interferon and Ribavirin —
-
AbbVie Receives Health Canada Approval of HOLKIRA TM PAK for the Treatment of Chronic Genotype 1 Hepatitis C
New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients – In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an overall 97 percent of GT1 HCV patients; additionally, 98 percent of patients completed treatment – HOLKIRA PAK was evaluated in more than 2,300 patients in over 25…
-
The Burden of Hepatitis C
-
PENDOPHARM ANNOUNCES PRIORITY REVIEW OF NEW THERAPY TO SUPPORT TREATMENT OF PATIENTS WITH HEPATITIS C
Montreal (Quebec), March 31, 2014 – New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest options, Pendopharm, a division of Pharmascience Inc., today announced that it has received a Priority Review designation from Health Canada for…
-
Action Hepatitis Canada NewsWire
TORONTO July 23 2014 /CNW/ – As we mark World Hepatitis Day (July 28th) people living with hepatitis C virus (HCV) have reason to feel hopeful. New cures for HCV are now available and more effective treatment options will hit the market in the future. Despite the increased hope there is concern. New cures are very…